Derek (More Plates More Dates) and the Ethics of Celebrity TRT Disclosure

Who Is Derek from More Plates More Dates?

Derek, known online as More Plates More Dates (MPMD), runs one of the largest English-language YouTube channels dedicated to hormone pharmacology, performance-enhancing drug analysis, and testosterone replacement therapy. His content sits at an unusual intersection: part bodybuilding culture, part clinical pharmacology review, part personal experimentation diary.

From Fitness Content to Pharmacology Commentary

Unlike many fitness influencers who discuss training and diet, Derek built his platform by analyzing blood work, dissecting drug protocols, and reviewing clinical literature on androgens and related compounds. He has publicly stated in multiple videos and podcasts that he has used testosterone, various SARMs, and other compounds over the years. This openness stands in contrast to the fitness industry norm, where influencers frequently deny or minimize pharmaceutical assistance [1].

The Marek Health and Gorilla Mind Connection

Derek co-founded Marek Health, a telehealth hormone optimization clinic, and owns Gorilla Mind, a supplement line. These commercial ventures create a specific disclosure dynamic. When he discusses TRT protocols or hormone optimization, he is simultaneously educating his audience and operating within a market he directly profits from. The FTC's Endorsement Guides (16 CFR 255) require that material connections between endorsers and products be clearly and conspicuously disclosed [2]. Derek generally includes disclaimers, though the consistency and prominence of these disclosures vary across his content.

What Has Derek Publicly Disclosed About His Own Protocol?

Derek has been more forthcoming about his personal pharmaceutical use than the vast majority of fitness influencers. Across hundreds of videos and podcast appearances, he has discussed specific compounds, doses, and bloodwork results.

Stated TRT and Hormone Use

In multiple YouTube videos and podcast interviews (including appearances on the Joe Rogan Experience and PBD Podcast), Derek has stated that he uses testosterone replacement therapy. He has discussed running testosterone at various doses, his experience with different esters, and his approach to managing estradiol through aromatase inhibitor use. He has also disclosed past use of SARMs and other investigational compounds.

This level of specificity is rare. A 2022 survey published in Health Communication found that only 5.5% of fitness influencer posts mentioning body composition also disclosed pharmaceutical or supplement use [3]. Derek's approach inverts that ratio. He discusses the pharmacology first.

Blood Work as Content

A recurring feature of Derek's content is public blood panel analysis. He has shared pre- and post-cycle blood work, lipid panels, liver enzymes, and hormone levels. The Endocrine Society's 2018 clinical practice guidelines recommend monitoring hematocrit, PSA, lipids, and testosterone levels during TRT, with follow-up at 3 to 6 months and then annually [4]. Derek's self-reported monitoring cadence appears to approximate these recommendations, though his protocols sometimes include compounds that fall outside guideline-endorsed TRT.

The Ethics of Disclosure: What the Literature Says

The question of whether celebrities and influencers should disclose pharmaceutical use, and how they should do it, touches medical ethics, advertising law, and public health.

Autonomy vs. Non-Maleficence

Medical ethics traditionally balances patient autonomy (the right to make informed decisions about one's body) against non-maleficence (the obligation to do no harm). When Derek shares his TRT protocol with an audience of millions, he exercises his own autonomy. The ethical tension arises from the downstream effect. A 2020 analysis in JAMA Internal Medicine found that testosterone prescribing in the United States increased 300% between 2001 and 2013, with direct-to-consumer advertising and cultural normalization identified as contributing factors [5]. Celebrity and influencer endorsement, whether explicit or implicit, compounds this trend.

The "Do as I Do" Problem

The American Medical Association's Code of Medical Ethics (Opinion 8.1) holds that physicians should not provide specific medical advice through media channels without establishing a patient-physician relationship [6]. Derek is not a physician, which places him outside this framework. But his content functions in a quasi-clinical capacity for many viewers. A 2023 cross-sectional study in Substance Use & Misuse found that 30.4% of young men who used anabolic-androgenic steroids cited social media as their primary information source for dosing and cycle design [7].

Partial Transparency Is Not Full Transparency

Derek's disclosure model is more transparent than most, but "more transparent" is not synonymous with "fully transparent." Several gaps exist.

First, compound sourcing. While Derek discusses what he takes, the sourcing of research chemicals and non-FDA-approved compounds is rarely addressed in detail. Compounding pharmacy quality varies significantly. A 2021 FDA investigation found that 28% of compounded hormone products tested were outside acceptable potency ranges [8].

Second, selection bias in blood work. Public blood panels are shared selectively. Viewers see the panels Derek chooses to post, not a complete longitudinal record. This can create an impression of health stability that may not reflect the full picture.

Third, risk communication. The Endocrine Society guidelines explicitly note that TRT carries risks including erythrocytosis (hematocrit above 54%), worsened obstructive sleep apnea, and suppression of spermatogenesis [4]. While Derek mentions these risks, the emphasis in his content typically falls on optimization rather than on the probability and severity of adverse outcomes.

Cardiovascular and Reproductive Risks of TRT: What Viewers Need to Know

Any discussion of TRT disclosure ethics must include the clinical risk profile that viewers may underestimate.

Cardiovascular Outcomes

The TRAVERSE trial (N=5,246), published in The New England Journal of Medicine in 2023, was the first large randomized controlled trial powered to assess cardiovascular safety of testosterone in men with hypogonadism and pre-existing or high risk of cardiovascular disease. The primary outcome (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (HR 0.96; 95% CI, 0.78 to 1.17), indicating non-inferiority but not cardiovascular benefit [9]. This trial provides the most rigorous data available, but it studied men aged 45 to 80 with documented hypogonadism. Derek's audience skews much younger, and many viewers may consider TRT without confirmed hypogonadism.

Fertility Suppression

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. A study in The Journal of Clinical Endocrinology & Metabolism demonstrated that testosterone administration leads to azoospermia or severe oligospermia in approximately 65% of men within 6 months [10]. For Derek's core audience of men in their 20s and 30s, this represents a significant reproductive risk that may not be fully appreciated when TRT is presented primarily as a performance and well-being intervention.

The Dose-Response Gap

Derek has discussed using testosterone at doses that sometimes exceed standard TRT ranges (typically 100 to 200 mg per week of testosterone cypionate or enanthate, per Endocrine Society guidelines [4]). Supraphysiologic doses carry additional risks, including accelerated erythrocytosis, dyslipidemia (specifically suppressed HDL cholesterol), and hepatic stress with oral androgens. The distinction between replacement and enhancement doses is medically significant, but this line can blur in content that discusses both interchangeably.

FTC, FDA, and the Regulatory Field for Influencer Drug Disclosure

The legal framework governing influencer pharmaceutical disclosure in the United States involves multiple agencies.

FTC Endorsement Requirements

The FTC's updated Endorsement Guides (effective 2023) require that endorsers disclose material connections "clearly and conspicuously," meaning the disclosure must be difficult to miss, in plain language, and close to the endorsement itself [2]. For a content creator who owns a supplement company and a telehealth clinic, nearly every discussion of hormones and supplements carries a material connection. Burying a disclosure in a video description box, rather than stating it verbally, may not meet the FTC's standard.

FDA Regulations on Unapproved Compounds

Several compounds Derek has discussed (including various SARMs and research peptides) are not FDA-approved for human use. The FDA issued a public safety advisory in 2017 warning consumers about SARMs marketed as dietary supplements, noting reports of liver toxicity, heart attack risk, and stroke [11]. Discussing personal use of unapproved compounds, while legal under the First Amendment, creates a specific ethical consideration: it can normalize substances for which no human safety or efficacy data from controlled trials exist.

Platform Responsibility

YouTube's medical misinformation policies prohibit content that contradicts health authority guidance on specific topics (primarily infectious diseases and vaccines), but do not extend to hormone therapy or PED use in any granular way. This leaves a regulatory gap. Content that a physician might consider reckless can circulate freely, while content creators bear no formal clinical accountability for viewer outcomes.

What Good Disclosure Would Actually Look Like

If the goal is genuinely informed consent for viewers, a disclosure model would need to include several elements that go beyond Derek's current approach (and far beyond what most influencers offer).

Elements of a Complete Disclosure Framework

A clinically responsible disclosure model for influencer pharmaceutical content would include: the specific compound, dose, frequency, and duration used; all concurrent medications and supplements; a comprehensive blood panel (not selectively curated) with timestamps; explicit acknowledgment of risks using quantitative data (e.g., "65% azoospermia rate at 6 months" rather than "it can affect fertility"); conflict-of-interest statements at the beginning of the content, not buried in descriptions; and a clear statement that individual protocols require physician supervision and should not be replicated without medical evaluation.

No influencer currently meets this standard. Derek comes closer than most. The gap between "closer than most" and "adequate" is where the ethical debate sits.

The Endocrine Society's Diagnostic Standard

The Endocrine Society's 2018 guidelines recommend diagnosing hypogonadism only after two morning total testosterone measurements below 300 ng/dL, combined with clinical symptoms such as decreased libido, erectile dysfunction, fatigue, or loss of body hair [4]. Content that encourages TRT exploration in men with testosterone levels within the normal reference range (300 to 1,000 ng/dL) effectively promotes off-label pharmaceutical use.

Derek's Influence in Context: The Broader Trend of Pharma-Fluencing

Derek does not operate in isolation. He is part of a broader shift in which social media creators function as de facto pharmaceutical educators.

Scale of the Problem

A 2024 systematic review in Drug Safety examined pharmaceutical promotion on social media platforms and found that 67% of health-related influencer content containing drug mentions lacked adequate risk disclosure [12]. The review called for regulatory frameworks specifically addressing influencer pharmaceutical promotion.

Comparison to Traditional DTC Advertising

Traditional direct-to-consumer (DTC) pharmaceutical advertising in the United States must include a "fair balance" of risk and benefit information, per FDA regulations (21 CFR 202.1) [13]. No equivalent requirement exists for influencer content. A 60-second television ad for testosterone gel must include side-effect warnings. A 60-minute YouTube video analyzing TRT protocols does not. This asymmetry means that influencer content, despite often being more detailed and engaging than a TV ad, can be less balanced in its risk communication.

The Role of Telehealth Clinics

The growth of telehealth testosterone clinics, including Derek's Marek Health, adds a layer of complexity. These clinics make TRT accessible to men who may not meet traditional diagnostic thresholds. A 2023 analysis in JAMA Network Open found that 42% of testosterone prescriptions from telehealth platforms were written for men whose testosterone levels did not meet the Endocrine Society's diagnostic criteria for hypogonadism [14]. When the content creator and the prescribing platform share a founder, the disclosure obligation becomes more acute.

What Viewers Should Do Before Considering TRT

For any viewer of Derek's content, or any similar channel, who is considering TRT, the clinical pathway should involve several concrete steps. Get two morning fasting testosterone measurements (drawn between 7:00 and 10:00 AM) through a licensed provider. Review symptoms with a board-certified endocrinologist or urologist. Discuss cardiovascular risk factors, particularly if you have a history of heart disease, given the TRAVERSE trial data [9]. Understand the fertility implications and consider sperm cryopreservation if future paternity is desired. Obtain baseline hematocrit, PSA, and lipid panels before initiating therapy, with follow-up labs at 3, 6, and 12 months per Endocrine Society recommendations [4].

A YouTube video, regardless of how well-researched, is not a substitute for this process.